close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bayer

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Bayer and Kumquat Biosciences Enter Global Exclusive License and Collaboration in Precision Oncology
From Bayer
Via Business Wire
News headline image
Bayer Provides Regulatory Update on Elinzanetant for the Treatment of Moderate to Severe Hot Flashes Due to Menopause
From Bayer
Via Business Wire
News headline image
One A Day® Launches First of its Kind Multivitamin Gummy with Iron to Help Fill Nutrient Gaps in Kids
From Bayer
Via Business Wire
News headline image
U.S. FDA Approves KERENDIA® (finerenone) to Treat Patients With Heart Failure With Left Ventricular Ejection Fraction ≥40% Following Priority Review
From Bayer
Via Business Wire
News headline image
BlueRock Therapeutics announces first patient receives investigational therapy in Phase 1/2a clinical trial of OpCT-001 for the treatment of primary photoreceptor diseases
From Bayer
Via Business Wire
News headline image
Bayer Appoints Priyal Patel as Chief Financial Officer for North America
From Bayer
Via Business Wire
News headline image
U.S. Supreme Court Asks for Views of Solicitor General in Durnell Case
From Bayer
Via Business Wire
News headline image
Bayer Files for Approval of gadoquatrane in the U.S.
From Bayer
Via Business Wire
News headline image
Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies
From Bayer
Via Business Wire
News headline image
U.S. FDA Approves NUBEQA® (darolutamide) to Treat Patients with Metastatic Castration-Sensitive Prostate Cancer
From Bayer
Via Business Wire
News headline image
Bayer to Share New Data from KERENDIA® (finerenone) Clinical Trial Program at European Renal Association Congress
From Bayer
Via Business Wire
News headline image
Elinzanetant Significantly Reduces Frequency of Moderate to Severe Vasomotor Symptoms Associated With Endocrine Therapy for Breast Cancer in Phase III Oasis-4 Study
From Bayer
Via Business Wire
News headline image
CORRECTING and REPLACING New XOFIGO® (radium-223 dichloride) Data in Metastatic Castration-Resistant Prostate Cancer from Phase III PEACE III Trial Published in Annals of Oncology
From Bayer
Via Business Wire
News headline image
U.S. FDA Accepts New Drug Application Under Priority Review for sevabertinib (BAY 2927088) in HER2-Mutant Non-Small Cell Lung Cancer
From Bayer
Via Business Wire
News headline image
ASCO 2025: XOFIGO® (radium-223 dichloride) Combination Data Showcases Clinical Benefits in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases
From Bayer
Via Business Wire
News headline image
ASCO 2025: Phase III ARANOTE Post-hoc Analyses Presented on Health-Related Quality of Life and Pain Outcomes in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving NUBEQA® (darolutamide) plus ADT
From Bayer
Via Business Wire
News headline image
Bayer Launches Centafore Imaging Core Lab to Support Imaging for Clinical Trials and Software as a Medical Device Development
From Bayer
Via Business Wire
News headline image
Bayer Highlights New Data from Oncology and Women’s Health Portfolios at 2025 ASCO Annual Meeting
From Bayer
Via Business Wire
News headline image
U.S. FDA Grants Approval for Jivi® Antihemophilic Factor (Recombinant), PEGylated-aucl in Pediatric Patients 7 to Under 12 Years of Age With Hemophilia A (Congenital Factor VIII Deficiency)
From Bayer
Via Business Wire
News headline image
Passage of New Georgia Bill a Win for Farmers
From Bayer
Via Business Wire
News headline image
Bayer U.S. Surveys Shed Further Light on the Diversity of Menopause Care Approaches and Menopause Symptom Experiences
From Bayer
Via Business Wire
News headline image
Don’t Let Corn Rootworm Steal Your Yield: Bayer Launches The Watch 2025
From Bayer
Via Business Wire
News headline image
AUA 2025: New Data from Post-Hoc Analyses Shared on Ultra-Low Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Hormone-Sensitive Prostate Cancer Receiving NUBEQA® (darolutamide) plus Androgen Deprivation Therapy (ADT)
From Bayer
Via Business Wire
News headline image
Bayer Initiates Phase I Study Targeting GPC3 With Actinium-225 Radiopharmaceutical in Patients With Advanced Hepatocellular Carcinoma
From Bayer
Via Business Wire
News headline image
Guru Ramamurthy Appointed as New CFO for Bayer’s Crop Science Division
From Bayer
Via Business Wire
News headline image
Agricultural Community Applauds Signing of New North Dakota Bill
From Bayer
Via Business Wire
News headline image
Bayer Unveils $44 Million Investment in Myerstown, PA Manufacturing Facility, Renewing Commitment to U.S. Innovation, Health and Community
From Bayer
Via Business Wire
News headline image
Bayer to Unveil Latest NUBEQA® (darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting
From Bayer
Via Business Wire
News headline image
U.S. FDA Grants Full Approval of VITRAKVI® (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors
From Bayer
Via Business Wire
News headline image
Bayer announces filing of petition to U.S. Supreme Court for review of Durnell Roundup™ case
From Bayer
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today